50
Views
0
CrossRef citations to date
0
Altmetric
Review

Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data

&
Pages 181-190 | Published online: 24 Dec 2022